Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine’s global reach.
Thursday, Day One and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in the U.S.) in pediatric low-grade glioma (pLGG) and “any future indications developed by Day One.”
Source: With $111M upfront investment, Ipsen secures ex-US rights to Day One’s pediatric cancer med